To learn more, visit Primes clinical insights on MASH
10.1089/152091501750220037 60 WhithamM.FebbraioM
Many patients report significant changes in hunger levels, fullness cues, and even food preferences
Item images, which may include product information when available
Similarly, patients with obesity and metabolic syndrome often exhibit chronic low-grade inflammation, and GLP-1 receptor agonists approved for weight management may address both adiposity and inflammatory burden simultaneously
Its part of a bigger picture that includes hormone support, sleep, and stress reduction. What the Latest Research Shows Evidence-Based and Backed by Science A 2024 study in The New England Journal of Medicine shows that patients on GLP-1 medications continued to lose weight for over a yearwith long-term maintenance when paired with expert oversight and lifestyle support